Literature DB >> 18036654

Vasoactive factors and hemodynamic mechanisms in the pathophysiology of portal hypertension in cirrhosis.

Angelo Gatta1, Massimo Bolognesi, Carlo Merkel.   

Abstract

Portal hypertension is primarily caused by the increase in resistance to portal outflow and secondly by an increase in splanchnic blood flow, which worsens and maintains the increased portal pressure. Increased portal inflow plays a role in the hyperdynamic circulatory syndrome, a characteristic feature of portal hypertensive patients. Almost all the known vasoactive systems/substances are activated in portal hypertension, but most authors stress the pathogenetic role of endothelial factors, such as COX-derivatives, nitric oxide, carbon monoxide. Endothelial dysfunction is differentially involved in different vascular beds and consists in alteration in response both to vasodilators and to vasoconstrictors. Understanding the pathogenesis of portal hypertension could be of great utility in preventing and curing the complications of portal hypertension, such as esophageal varices, hepatic encephalopathy, ascites.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18036654     DOI: 10.1016/j.mam.2007.09.006

Source DB:  PubMed          Journal:  Mol Aspects Med        ISSN: 0098-2997


  13 in total

1.  Penicillar arterioles of red pulp in residual spleen after subtotal splenectomy due to splenomegaly in cirrhotic patients: a comparative study.

Authors:  Xiaoji Zhu; Wei Han; Lei Wang; Haibo Chu; Jianhua Zhao; Yongbo Xu; Tao Wang; Wenjun Guo
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

2.  Association between spleen volume and the post-hepatectomy liver failure and overall survival of patients with hepatocellular carcinoma after resection.

Authors:  Jae Seok Bae; Dong Ho Lee; Jeongin Yoo; Nam-Joon Yi; Kwang-Woong Lee; Kyung-Suk Suh; Haeryoung Kim; Kyung Bun Lee
Journal:  Eur Radiol       Date:  2020-10-07       Impact factor: 5.315

3.  Effect of TIPS placement on portal and splanchnic arterial blood flow in 4-dimensional flow MRI.

Authors:  Zoran Stankovic; Martin Rössle; Wulf Euringer; Michael Schultheiss; Riad Salem; Alex Barker; James Carr; Mathias Langer; Michael Markl; Jeremy D Collins
Journal:  Eur Radiol       Date:  2015-04-08       Impact factor: 5.315

Review 4.  Extrahepatic complications to cirrhosis and portal hypertension: haemodynamic and homeostatic aspects.

Authors:  Søren Møller; Jens H Henriksen; Flemming Bendtsen
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

5.  Vasopressin deficiency and vasodilatory state in end-stage liver disease.

Authors:  Gebhard Wagener; Galina Kovalevskaya; Moury Minhaz; Fallon Mattis; Jean C Emond; Donald W Landry
Journal:  J Cardiothorac Vasc Anesth       Date:  2010-12-03       Impact factor: 2.628

6.  Non-selective β-blockers improve the correlation of liver stiffness and portal pressure in advanced cirrhosis.

Authors:  T Reiberger; A Ferlitsch; B A Payer; M Pinter; M Homoncik; M Peck-Radosavljevic
Journal:  J Gastroenterol       Date:  2011-12-15       Impact factor: 7.527

Review 7.  Splanchnic vasodilation and hyperdynamic circulatory syndrome in cirrhosis.

Authors:  Massimo Bolognesi; Marco Di Pascoli; Alberto Verardo; Angelo Gatta
Journal:  World J Gastroenterol       Date:  2014-03-14       Impact factor: 5.742

8.  Decompensated liver cirrhosis and neural regulation of mesenteric vascular tone in rats: role of sympathetic, nitrergic and sensory innervations.

Authors:  Esther Sastre; Laura Caracuel; Isabel Prieto; Pablo Llévenes; M Ángeles Aller; Jaime Arias; Gloria Balfagón; Javier Blanco-Rivero
Journal:  Sci Rep       Date:  2016-08-03       Impact factor: 4.379

Review 9.  Management of refractory ascites in cirrhosis: Are we out of date?

Authors:  Alagappan Annamalai; Lauren Wisdom; Megan Herada; Mazen Nourredin; Walid Ayoub; Vinay Sundaram; Andrew Klein; Nicholas Nissen
Journal:  World J Hepatol       Date:  2016-10-08

10.  Role of estrogen receptor β selective agonist in ameliorating portal hypertension in rats with CCl4-induced liver cirrhosis.

Authors:  Cheng-Gang Zhang; Bin Zhang; Wen-Sheng Deng; Ming Duan; Wei Chen; Zhi-Yong Wu
Journal:  World J Gastroenterol       Date:  2016-05-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.